Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Hims & Hers Health's Debt-to-EBITDA or its related term are showing as below:
CHIX:82Wd'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.5 Med: -0.04 Max: 30.13
Current: 30.13
During the past 7 years, the highest Debt-to-EBITDA Ratio of Hims & Hers Health was 30.13. The lowest was -0.50. And the median was -0.04.
CHIX:82Wd's Debt-to-EBITDA is ranked worse than 97.39% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs CHIX:82Wd: 30.13
Hims & Hers Health (CHIX:82Wd) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Hims & Hers Health Debt-to-EBITDA Related Terms
Hims & Hers Health Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Hims & Hers Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hims & Hers Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hims & Hers Health Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hims & Hers Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hims & Hers Health's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Hims & Hers Health (CHIX:82WD) has a Debt-to-EBITDA of -5.02 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hims & Hers Health. According to the industry distribution chart, Hims & Hers Health ranks #672 out of 690 companies in the Drug Manufacturers industry, placing it in the top 97.4%.
Is Hims & Hers Health's Debt-to-EBITDA too high?
Hims & Hers Health's current Debt-to-EBITDA is -5.02. Based on the distribution chart, Hims & Hers Health ranks #672 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hims & Hers Health has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hims & Hers Health's Debt-to-EBITDA compare to ?
According to the Drug Manufacturers industry distribution chart, Hims & Hers Health ranks #672 out of 690 companies for Debt-to-EBITDA. This places Hims & Hers Health in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hims & Hers Health. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hims & Hers Health's current Debt-to-EBITDA is -5.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hims & Hers Health stock overvalued right now?
Based on GuruFocus' analysis, Hims & Hers Health (CHIX:82WD) is currently considered Fairly Valued. The stock's GF Value™ is €32.41, compared to a current price of €30.46 — trading 6% below its estimated fair value. The current Debt-to-EBITDA is -5.02. Hims & Hers Health's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Hims & Hers Health (CHIX:82WD), the current Debt-to-EBITDA is -5.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hims & Hers Health (CHIX:82WD) Overvalued in 2026?
Based on GuruFocus' analysis, Hims & Hers Health stock appears to be undervalued.
The current stock price of €30.46 is trading 6% below its estimated GF Value™ of €32.41.
GuruFocus considers Hims & Hers Health to be Fairly Valued.
Key valuation signals for CHIX:82WD:
Debt-to-EBITDA: -5.02
GF Value™: €32.41 vs. price of €30.46 (6% below fair value)
No single metric tells the full story. See the CHIX:82WD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
60GF Score
Get the complete analysis for CHIX:82WD
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:82WD has been successfully added to your 
